Research on Intervention Mechanism of Tanshinone Type IIA Sulfonate of Adriamycin Nephrosis Rats Kidney Injury
Lv B
Abstract
Lv B
Abstract
Objective: To observe the effects of tanshinone type IIA sulfonate of adriamycin nephrosis rats quantitative24 h urine protein,blood plasma viscosity,histopathologic morphology,kidney tissues TGF- 1 and PAI- 1 and to explore its mechanism. Methods: SD male rats were randomly divided into blank group,model group,positive control group,tanshinone ⅡA low dose group,tanshinoneⅡA high dose group. Adriamycin nephrosis model was established by injection of adriamycin the tail intravenous,3 weeks after injection,each dose group were given corresponding doses of intraperitoneal injection of drugs. 2 weeks later,test the 24 hours urinary protein quantitative,pathological way form,kidney tissues TGF- 1 and PAI- 1 expressions. Results: Tanshinone type IIA sulfonate can reduce adriamycin nephrosis rats 24 hours urinary protein quantitative,improve blood viscosity,kidney tissues PAI- 1and TGF- β1 expressions and compared with model control group there was significant difference( P 0. 05). Conclusion: Tanshinone type IIA sulfonate may be by reducing the 24 h urine protein quantitative and improving pathological tissue damage and inhibiting kidney tissues TGFβ- 1 and PAI- 1 to treat adriamycin nephropathy.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: To observe the effects of tanshinone type IIA sulfonate of adriamycin nephrosis rats quantitative24 h urine protein,blood plasma viscosity,histopathologic morphology,kidney tissues TGF- 1 and PAI- 1 and to explore its mechanism. Methods: SD male rats were randomly divided into blank group,model group,positive control group,tanshinone ⅡA low dose group,tanshinoneⅡA high dose group. Adriamycin nephrosis model was established by injection of adriamycin the tail intravenous,3 weeks after injection,each dose group were given corresponding doses of intraperitoneal injection of drugs. 2 weeks later,test the 24 hours urinary protein quantitative,pathological way form,kidney tissues TGF- 1 and PAI- 1 expressions. Results: Tanshinone type IIA sulfonate can reduce adriamycin nephrosis rats 24 hours urinary protein quantitative,improve blood viscosity,kidney tissues PAI- 1and TGF- β1 expressions and compared with model control group there was significant difference( P 0. 05). Conclusion: Tanshinone type IIA sulfonate may be by reducing the 24 h urine protein quantitative and improving pathological tissue damage and inhibiting kidney tissues TGFβ- 1 and PAI- 1 to treat adriamycin nephropathy.
Key concepts: Nephrosis, Kidney, Urine, Intraperitoneal injection, Medicine, Pathological, Nephropathy, Nephrotic syndrome